The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030
The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030

The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030

Screening small molecule fragments hasmade it possible to identify pharmacological leads against otherwise hard totarget hotspots on biomolecules, such as allosteric sites, rendering thisapproach a valuable alternative method of drug discovery

 

Roots Analysis is pleased to announce the publication of its recent study,titled, “Fragment-based Drug Discovery Market:Library and Service Providers, 2020-2030.”

 

Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of this approach over the next decade.It features an in-depth analysis, highlighting the capabilities of variousstakeholders engaged in this domain. In addition to other elements, the studyincludes:

§ A detailed review ofthe overall landscape of fragment-based drug discovery library and serviceproviders. 

§ Elaborate profiles ofthe companies providing libraries and services for fragment-based drugdiscovery (shortlisted on the basis of the service portfolio and number offragment screening techniques offered).

§ An analysis of thepartnerships that have been established in the recent past.

§ A detailed analysison acquisition targets.

§ An insightfulcompetitiveness analysis of fragment-based drug discovery library and serviceproviders.

§ An analysishighlighting the cost saving potential associated with the use offragment-based drug discovery approach.

§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)

  • Type of Technique

§ X-ray Crystallography

§ Nuclear MagneticResonance

§ Surface PlasmonResonance

§ Other ScreeningTechniques

  • Type of Service

§ Library Screening

§ Fragment Screening

§ Fragment Optimization

  • End User

§ Industry Players

§ Non-Industry Players

  • Key Geographical Region 

§ North America (US andCanada)

§ Europe (UK, France,Germany, Spain, Italy, and rest of Europe)

§ Asia-Pacific (China,Japan, India, and rest of Asia-Pacific / rest of the world)

 

Key companies covered in the report:

§  2bind

§  Charles River Laboratories

§  ChemAxon

§  ComInnex

§  Creative Biolabs

§  Creative Biostructure

§  CRELUX

§  Domainex

§  Evotec

§  Red Glead Discovery

Press Release: Variation 1 (Format 2)

 

§  SARomics Biostructures

§  Shanghai ChemPartner

§  Sygnature Discovery

§  Vernalis Research

 

Formore information, please click on the following link: 

https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

 

Other recent offerings

1.     DNA-EncodedLibraries: Platforms and Services Market

2.     AntibodyDiscovery: Services and Platforms Market (2nd Edition), 2018-2028

3.     InSilico / Computer-Aided Drug Discovery Services Market: Focus on LargeMolecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy andVectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment BasedDrug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery,Interface Based Drug Discovery Approaches)

 

About Roots Analysis

Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots AnalysisPrivate Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com